TVTX - Travere Therapeutics Inc logo

Travere Therapeutics Inc

TVTX

Travere Therapeutics develops and commercializes therapies for rare kidney and metabolic diseases. Its products include FILSPARI for IgA Nephropathy and Thiola for cystinuria, along with clinical-stage programs targeting additional rare conditions.

โš•๏ธ Healthcare NASDAQ Listed 2012 $ USD
$1,000 invested 20 years ago โ†’$27,822today

Score Overview

1 Year
Score
Net Growth-70.14%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth20.50%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.7
Net Growth75.87%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth348.54%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth9.27%
Net Trend20%
Net Income Consistency
Rev Growth342.64%
Rev Trend80%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-43.24%
Net Trend21%
Net Income Consistency
Rev Growthโ€”
Rev Trend83%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Travere Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. TVTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 50.08โ€”
1 Year2025-10-23
$ 28.1577.90%
5 Years2021-10-22
$ 26.2890.56%
10 Years2016-10-21
$ 20.58143.34%
20 Years2006-10-23
$ 1.8027x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 591M-$ 43M$ 489M
2025$ 490M-$ 25M$ 322M
2024$ 233M-$ 321M$ 370M
2023$ 145M-$ 111M$ 566M
2022$ 109M-$ 278M$ 450M
2021$ 131M-$ 180M$ 552M
2020$ 198M-$ 169M$ 361M
2019$ 175M-$ 146M$ 398M
2018$ 164M-$ 102M$ 471M
2017$ 154M-$ 59M$ 300M
2016$ 133M-$ 47M$ 255M
2015$ 99M$ 117M$ 229M
2014$ 28M-$ 110M$ 27M
2013-$ 33M$ 6M
IPO2012-$ 30M$ 11.39K
TVTX - Travere Therapeutics Inc logo

Travere Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 198M to $ 490M and net income went from -$ 169M to -$ 25M. Revenue increased in 4 of those 5 years; net income in 2.

Between 2015 and 2025, revenue grew from $ 99M to $ 490M and net income went from $ 117M to -$ 25M. Revenue increased in 8 of those 10 years; net income in 2.

Travere Therapeutics Inc currently holds a 5-year HDB Score of 5.7 out of 10. How the HDB Score is calculated.

Membership

Explore TVTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies